Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
Inflamm Bowel Dis
.
2022 May 4;28(5):817.
doi: 10.1093/ibd/izab270.
Authors
Jurij Hanzel
1
2
,
Erwin Dreesen
3
4
,
Séverine Vermeire
5
,
Mark Löwenberg
2
,
Frank Hoentjen
6
,
Peter Bossuyt
7
,
Esmé Clasquin
2
,
Filip J Baert
8
,
Geert R D'Haens
2
,
Ron Mathôt
9
Affiliations
1
Faculty of Medicine, University of Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia.
2
Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.
3
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
4
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
5
Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
6
Department of Gastroenterology and Hepatology, Radboud UMC, Nijmegen, the Netherlands.
7
Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium.
8
Division of Gastroenterology, AZ Delta, Roeselare, Belgium.
9
Department of Hospital Pharmacy-Clinical Pharmacology, Amsterdam UMC, Amsterdam, the Netherlands.
PMID:
34788812
PMCID:
PMC9071094
DOI:
10.1093/ibd/izab270
No abstract available
Publication types
Published Erratum